Immunology Program
The Michael Glickman Lab
Research
Professor
We are broadly interested in the biology of mycobacteria, which include the major human pathogen M. tuberculosis, the nonpathogenic model organism M. smegmatis, and the cancer biotherapeutic agent BCG.
Research Projects
Featured News
Publications Highlights
Distinctive roles of translesion polymerases DinB1 and DnaE2 in diversification of the mycobacterial genome through substitution and frameshift mutagenesis, P Dupuy, S Ghosh, O Adefisayo, J Buglino, S Shuman, MS Glickman, Nature Communications 13 (1), 4493
Roles for mycobacterial DinB2 in frameshift and substitution mutagenesis, P Dupuy, S Ghosh, A Fay, O Adefisayo, R Gupta, S Shuman, …Elife 12, e83094
People
Michael S. Glickman, MD
Professor
- Physician-scientist Michael Glickman investigates the physiology and pathogenic mechanisms of mycobacteria, including the use of mycobacteria as bacterial cancer therapies.
- MD, Columbia University College of Physicians and Surgeons
- [email protected]
- Email Address
- 646-888-2368
- Office Phone
- View physician profile
- Physician profile
Members
Lab Alumni
Open Positions
To learn more about available postdoctoral opportunities, please visit our Career Center
To learn more about compensation and benefits for postdoctoral researchers at MSK, please visit Resources for Postdocs
Get in Touch
-
Lab Head Email
-
Office Phone
-
Office Fax
-
Lab Phone
-
Lab Fax
Disclosures
Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.
MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.
Michael S. Glickman discloses the following relationships and financial interests:
-
Fimbrion Therapeutics, Inc.
Professional Services and Activities (Uncompensated)
-
Vedanta
Equity; Professional Services and Activities
The information published here is a complement to other publicly reported data and is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.
This page and data include information for a specific MSK annual disclosure period (January 1, 2023 through disclosure submission in spring 2024). This data reflects interests that may or may not still exist. This data is updated annually.
Learn more about MSK’s COI policies here. For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at [email protected].